Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Medtronic
AstraZeneca
Cipla
Harvard Business School
Moodys

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 9,493,524

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,493,524
Title:Methods for treatment of stroke or cerebrovascular accidents using an ET.sub.B receptor agonist
Abstract: Methods of using an ET.sub.B receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ET.sub.B receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.
Inventor(s): Gulati; Anil (Naperville, IL)
Assignee: MIDWESTERN UNIVERSITY (Downers Grove, IL)
Application Number:14/149,785
Patent Claims:see list of patent claims

Details for Patent 9,493,524

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01 ➤ Sign Up MIDWESTERN UNIVERSITY (Downers Grove, IL) 2027-08-21 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; MULTIDOSE 103234 002 1989-06-01 ➤ Sign Up MIDWESTERN UNIVERSITY (Downers Grove, IL) 2027-08-21 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; MULTIDOSE 103234 003 1989-06-01 ➤ Sign Up MIDWESTERN UNIVERSITY (Downers Grove, IL) 2027-08-21 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 004 1989-06-01 ➤ Sign Up MIDWESTERN UNIVERSITY (Downers Grove, IL) 2027-08-21 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 005 1989-06-01 ➤ Sign Up MIDWESTERN UNIVERSITY (Downers Grove, IL) 2027-08-21 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Federal Trade Commission
Harvard Business School
McKesson
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.